等待開盤 11-04 09:30:00 美东时间
+0.025
+0.13%
Immatics ( ($IMTX) ) has shared an update. On October 23, 2026, Immatics report...
10-23 19:57
Marker Therapeutics, Inc. has received a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its lead investigational MAR-T cell therapy, MT-601, for patients with locally advanced unresectable pancreatic cancer. The funding reflects independent validation of the scientific rationale behind the company's multi-antigen recognizing T cell platform, which targets tumor heterogeneity and antigen esc...
10-19 11:00